Literature DB >> 3536747

Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.

J M Small, T G Mitchell.   

Abstract

Strains 6, 15, 98, 110, and 145 of Cryptococcus neoformans serotype A vary in capsule size, animal virulence, and susceptibility to in vitro phagocytosis. The isolated capsular polysaccharides (CPSs) differ in monosaccharide composition ratios and molecular size, as determined by gel filtration. The purpose of this investigation was to characterize the binding of CPSs to capsule-free mutants of C. neoformans and to examine CPSs from these strains for differences in their ability to bind, to determine whether such differences might explain the variation in the pathobiology of these strains. CPSs were partially periodate oxidized, tyraminated, iodinated with 125I, and used in binding studies with two capsule-free mutants of C. neoformans, strain 602 and Cap59. Binding was specific for yeast species and for polysaccharide and was saturable, which is consistent with a receptor-mediated mechanism of attachment. Binding occurred rapidly and was only slowly reversible. Binding was also independent of pH from pH 5.5 to 8, of cation concentrations, and of competition by sugars up to 1.0 M concentrations. Only a portion of CPS was capable of binding, and strains varied in the extent to which their CPS bound. CPS-15-IV (peak IV was the major polysaccharide peak on DEAE-cellulose chromatography of CPS from strain 15) had the highest proportion of binding (40%), followed by CPS from strains 98, 6, 145, 110, and 15-III (peak III was an earlier eluting fraction of CPS from strain 15). The CPSs differed similarly in their ability to competitively inhibit binding. Treatment of CPS, but not yeast cells, with proteinase XIV abolished binding without altering the CPS gross structure. Treatment of yeast cells with proteases, heat, or formaldehyde did not alter binding, and both strain 602 and Cap59 bound CPS similarly. Binding to encapsulated yeast cells was minimal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536747      PMCID: PMC260232          DOI: 10.1128/iai.54.3.742-750.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

2.  Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans.

Authors:  E S Jacobson; D J Ayers; A C Harrell; C C Nicholas
Journal:  J Bacteriol       Date:  1982-06       Impact factor: 3.490

3.  Capsular polysaccharides from a parent strain and from a possible, mutant strain of Cryptococcus neoformans serotype A.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1981-09-16       Impact factor: 2.104

4.  A radioimmunoassay for antibody to pneumococcal polysaccharides.

Authors:  A A Latif; A D Webster
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

5.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

Authors:  T R Kozel; C A Hermerath
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

6.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

7.  In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans.

Authors:  T G Mitchell; L Friedman
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441

8.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

9.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

10.  Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.

Authors:  J F Breen; I C Lee; F R Vogel; H Friedman
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more
  14 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

3.  Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages.

Authors:  J N Steenbergen; H A Shuman; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

4.  Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes.

Authors:  C Retini; A Vecchiarelli; C Monari; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils.

Authors:  C Retini; A Vecchiarelli; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 6.  The Cryptococcus neoformans capsule: a sword and a shield.

Authors:  Teresa R O'Meara; J Andrew Alspaugh
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 7.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.

Authors:  M F Miller; T G Mitchell
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

9.  Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.

Authors:  C H Mody; R M Syme
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.